Can-Fite BioPharma (CANF) Competitors $1.09 0.00 (0.00%) As of 04/30/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CANF vs. ALLR, CMMB, EDSA, SLGL, EQ, NAII, LPCN, CING, UBX, and BFRGShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Allarity Therapeutics (ALLR), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), Sol-Gel Technologies (SLGL), Equillium (EQ), Natural Alternatives International (NAII), Lipocine (LPCN), Cingulate (CING), Unity Biotechnology (UBX), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Allarity Therapeutics Chemomab Therapeutics Edesa Biotech Sol-Gel Technologies Equillium Natural Alternatives International Lipocine Cingulate Unity Biotechnology Bullfrog AI Allarity Therapeutics (NASDAQ:ALLR) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, community ranking, profitability, media sentiment, valuation and analyst recommendations. Do analysts rate ALLR or CANF? Can-Fite BioPharma has a consensus price target of $14.00, indicating a potential upside of 1,184.40%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media refer more to ALLR or CANF? In the previous week, Allarity Therapeutics had 2 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 3 mentions for Allarity Therapeutics and 1 mentions for Can-Fite BioPharma. Allarity Therapeutics' average media sentiment score of 0.79 beat Can-Fite BioPharma's score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in ALLR or CANF? Can-Fite BioPharma received 9 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. However, 50.00% of users gave Allarity Therapeutics an outperform vote while only 12.20% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Can-Fite BioPharmaOutperform Votes1012.20%Underperform Votes7287.80% Is ALLR or CANF more profitable? Can-Fite BioPharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% Can-Fite BioPharma N/A N/A N/A Which has preferable valuation and earnings, ALLR or CANF? Can-Fite BioPharma has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/ACan-Fite BioPharma$674K5.72-$7.63M-$1.79-0.61 Which has more risk and volatility, ALLR or CANF? Allarity Therapeutics has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Do institutionals and insiders believe in ALLR or CANF? 11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCan-Fite BioPharma beats Allarity Therapeutics on 12 of the 15 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.86M$6.90B$5.57B$18.97BDividend YieldN/A3.06%5.11%4.03%P/E Ratio-0.617.4422.4232.71Price / Sales5.72242.72394.1027.84Price / CashN/A65.8538.1817.53Price / Book0.626.516.774.47Net Income-$7.63M$143.21M$3.22B$1.02B7 Day Performance-7.63%3.95%3.25%2.26%1 Month Performance-26.29%0.34%0.01%-2.86%1 Year Performance-47.34%2.58%18.00%5.48% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.6584 of 5 stars$1.09flat$14.00+1,184.4%-47.3%$3.86M$674,000.00-0.618Gap UpALLRAllarity Therapeutics0.3037 of 5 stars$1.03+9.6%N/A-96.9%$17.53MN/A0.0010CMMBChemomab Therapeutics3.585 of 5 stars$1.16+3.6%$9.00+675.9%+92.9%$16.66MN/A-1.1620Upcoming EarningsShort Interest ↓News CoverageGap UpEDSAEdesa Biotech3.0965 of 5 stars$2.38+5.3%$21.00+782.4%-47.6%$16.64MN/A-1.2720Short Interest ↓Positive NewsSLGLSol-Gel Technologies2.3656 of 5 stars$0.59+6.4%$5.00+754.7%+6.7%$16.30M$11.71M-1.7250Gap DownHigh Trading VolumeEQEquillium2.7926 of 5 stars$0.46-3.7%$3.00+559.1%-71.8%$16.26M$41.10M-3.2540Upcoming EarningsShort Interest ↓Positive NewsGap DownNAIINatural Alternatives International0.8436 of 5 stars$2.61-6.1%N/A-52.0%$16.18M$121.85M-2.02290Gap DownHigh Trading VolumeLPCNLipocine2.5453 of 5 stars$3.01+0.3%$10.00+232.2%-28.4%$16.10M$11.20M-3.9610Upcoming EarningsAnalyst ForecastNews CoverageCINGCingulate2.4774 of 5 stars$4.07-4.0%$30.67+653.5%+350.8%$16.04MN/A-0.2820Short Interest ↑UBXUnity Biotechnology4.1077 of 5 stars$0.94-3.1%$5.33+467.6%-26.6%$15.85M$240,000.00-0.7260Analyst RevisionBFRGBullfrog AI0.4742 of 5 stars$1.66flatN/A-43.6%$15.63M$60,000.00-1.954Short Interest ↑ Related Companies and Tools Related Companies Allarity Therapeutics Alternatives Chemomab Therapeutics Alternatives Edesa Biotech Alternatives Sol-Gel Technologies Alternatives Equillium Alternatives Natural Alternatives International Alternatives Lipocine Alternatives Cingulate Alternatives Unity Biotechnology Alternatives Bullfrog AI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CANF Stock Free CANF Stock Alerts